Archive · 24 Jul 2025
Lupin Receives US FDA Approval for Generic Diabetes Drugs
Lupin, a drug company, got permission from the US government to sell generic versions of two diabetes medicines.
One is like a medicine called Victoza, used to help adults and kids with type 2 diabetes.
The other is like a medicine called Glucagon, used for people with diabetes who have very low blood sugar.
Lupin will make these medicines in Nagpur.
This helps more people get access to important diabetes treatments.
Lupin received USFDA approval for generic diabetes medications.
The approval covers Liraglutide Injection and Glucagon for Injection.
Liraglutide Injection is bioequivalent to Novo Nordisk's Victoza.
Glucagon for Injection is bioequivalent to Eli Lilly's product.
The products will be manufactured in Nagpur.
- Who
- Lupin, USFDA, Novo Nordisk, and Eli Lilly and Company.
- What
- Lupin received USFDA approval for generic diabetes drugs.
- When
- Approval announced on July 24, 2025
- Where
- USFDA approval, products manufactured in Nagpur.
- Why
- To expand access to critical therapies for patients.
- Company
- Lupin
- Approval Received From
- USFDA
- Generic Drugs
- Liraglutide Injection, Glucagon for Injection
- Liraglutide Equivalent
- Victoza Injection
- Glucagon Equivalent
- Glucagon for Injection, 1 mg/vial
- Manufacturing Location
- Nagpur
- Liraglutide Estimated Annual US Sales
- $458 million (May 2025)
- Glucagon Estimated Annual US Sales
- $124 million